Abstract
The clinical application of multi-drug resistance reversal agents is greatly limited due to its severe side-effects and interference in pharmacokinetics of chemotherapeutic agents. Multi-drug resistance reversal agents haven' t been applicated in clinic successfully. The third generation multi- drug resistance reversal agents, including gefitinib and GF120918, etc, has promising prospect. Key words: Neoplasms ; Drug tolerance ; Carrier proteins
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
